Activity of topically applied methylprednisolone aceponate in relation to other topical glucocorticosteroids in healthy volunteers
- PMID: 8457237
Activity of topically applied methylprednisolone aceponate in relation to other topical glucocorticosteroids in healthy volunteers
Abstract
Topical glucocorticosteroids are useful in the treatment of various skin diseases. Although there are already many corticosteroids available, there is still need for highly potent and well tolerated ones. The anti-inflammatory activity of methylprednisolone aceponate (MPA, CAS 86401-95-8) has been investigated in 165 healthy volunteers of either sex. UV-B irradiation or cellophane tape stripping has served to produce erythema. First, the dose response relationship of MPA ointment (0.01%, 0.05%, 0.1% and 0.5%) has been evaluated. MPA effects have been related to those of the vehicle and difluocortolone 21-valerate 0.1% (DFV) ointment. Then the activity of 0.1% MPA (cream, ointment and fatty ointment) has been related to those of the respective vehicles as well as commercially available preparations of five corticosteroids: betamethasone 17,21-dipropionate 0.64% (BDP), betamethasone 17-valerate 0.1% (BV), clobetasol 17-propionate 0.05% (CP), hydrocortisone 17-butyrate 0.1% (HCB), prednicarbate 0.25% (P). In each experiment, MPA activity significantly exceeded that of the respective vehicle (p < or = 0.05). MPA 0.01-0.5% ointment exhibited strong anti-inflammatory activity, at least corresponding to that of 0.1% DFV ointment. A dose-dependent activity could only be observed in the UV-B-erythema test using 3 fold MED (minimal erythema doses) for irradiation, a test model differentiating strong corticosteroids. The comparison of 0.1% MPA formulations with respective reference preparations showed the following results: On stripped skin no significant differences could be detected which is demonstrated in the example of cream formulations.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Dose-response relationship of topically applied methylprednisolone aceponate (MPA) in healthy volunteers.Eur J Clin Pharmacol. 1992;43(2):157-9. doi: 10.1007/BF01740663. Eur J Clin Pharmacol. 1992. PMID: 1425873 Clinical Trial.
-
Assessment of topical corticosteroid activity using the vasoconstriction assay in healthy volunteers.Skin Pharmacol Physiol. 2007;20(3):133-40. doi: 10.1159/000098164. Epub 2006 Dec 21. Skin Pharmacol Physiol. 2007. PMID: 17191036 Clinical Trial.
-
Activity of different desoximetasone preparations compared to other topical corticosteroids in the vasoconstriction assay.Skin Pharmacol Physiol. 2008;21(3):181-7. doi: 10.1159/000131082. Epub 2008 Jun 3. Skin Pharmacol Physiol. 2008. PMID: 18523415 Clinical Trial.
-
Methylprednisolone aceponate in eczema and other inflammatory skin disorders -- a clinical update.Int J Clin Pract. 2006 Jan;60(1):85-92. doi: 10.1111/j.1368-5031.2005.00754.x. Int J Clin Pract. 2006. PMID: 16409433 Review.
-
Topical hydrocortisone 17-butyrate 21-propionate in the treatment of inflammatory skin diseases: pharmacological data, clinical efficacy, safety and calculation of the therapeutic index.Pharmazie. 2016 Mar;71(3):115-21. Pharmazie. 2016. PMID: 27183704 Review.
Cited by
-
Topical glucocorticoids with improved risk-benefit ratio. Rationale of a new concept.Drug Saf. 1996 Jun;14(6):375-85. doi: 10.2165/00002018-199614060-00003. Drug Saf. 1996. PMID: 8828015 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Miscellaneous